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Introduction 
Patients relapsing after allogeneic hematopoietic stem cell
transplantation (HSCT) for chronic myeloid leukemia (CML)
can be treated either with tyrosine kinase inhibitors (TKI) or
by the administration of donor lymphocyte infusion (DLI) or
both.1 The best strategy, with respect to using either or both
of DLI and TKI, and the timing of these in relation to the
relapse has not yet been established.
The description of the graft-versus-leukemia (GvL) effect
has paved the way to the development of DLI for the treat-
ment of relapse in patients after allogeneic HSCT.2-7 DLI is
most effective in CML.5 It can restore remission in many
patients with CML relapsing after HSCT.2-4 As responses are
less frequent for advanced disease at the time of relapse,
molecular/cytogenetic monitoring after transplantation and
prompt therapy with DLI prior to developing hematologic
relapse may represent the optimal management of patients
after transplantation.8 The applicability of DLI in CML has
been limited by morbidity and mortality associated with
graft-versus-host disease (GvHD).7,9-11 The practice of DLI has
changed as the early bulk doses have been replaced by regi-
mens with low starting doses followed by escalation until
response or GvHD. This may reduce the severity of GvHD,
while possibly preserving GvL effects.5,12-14 
Over the past decade TKI have been available to treat
patients who relapse after allogeneic HSCT. Durable respons-
es have been reported with imatinib, nilotinib and dasatinib,
and many of these patients had previously failed to respond
to DLI. Modern practice has favored the use of a TKI prior to
DLI because of the risk of inducing GvHD, but this is compli-
cated by the fact that many CML patients are now only trans-
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Patients with chronic myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation may be
treated by tyrosine kinase inhibitors and/or by donor lymphocyte infusions. The best strategies and timing of
administration of lymphocytes are unclear. We analyzed 155 patients who relapsed after allogeneic stem cell trans-
plantation with disease detectable only by molecular methods and who subsequently received lymphocytes.
Transplants were performed in first chronic phase (n=125) or in advanced disease (n=29) from identical siblings
(n=84) or unrelated donors (n=71) between 1986 and 2003. They received lymphocytes either during molecular
relapse (n=85) or upon progression to more advanced disease (1993 to 2004). The median interval from relapse to
lymphocyte infusion was 210 (0-1673) days.  The median follow up after it was 46 (3-135) months. Overall sur-
vival was 76±4% at five years after lymphocyte infusions (89±8% with sibling donors and 63±13% with unrelat-
ed donors (P=0.003)). Survival was 69±14% when lymphocytes were given within six months of the detection of
molecular relapse and 81±10% (P=0.061) when given later; 81±11% if given at molecular relapse versus 71±12%
(P=0.26) with more advanced disease. In multivariate analysis survival was worse if the donor was unrelated (HR
2.54 (95% CI: 1.15-5.53), P=0.021) and better with lymphocyte infusions beyond six months from molecular
relapse (HR 0.4 (95%CI: 0.19-0.84), P=0.018). These data confirm the remarkable efficacy of lymphocyte infusions
for this disease. There appears to be no advantage from administering it early upon detection of molecular relapse
in patients who received allogeneic stem cell transplantation for chronic myeloid leukemia.
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ABSTRACT
planted because of failure to several TKIs. Therefore, the
question of when relapse should be treated with DLI or
TKI remains important.
Methods 
This study was conducted by the Chronic Malignancies
Working Party (CMWP) of the EBMT (European Group
for Blood and Marrow transplantation). We set out to
study patients who had had their relapse first detected as
molecular relapse. The initial total sample included 1045
patients from 138 EBMT centers who had received DLI as
treatment of relapse at any disease stage (molecular or
more advanced) between 1993 and 2004. Specific ques-
tionnaires related to DLI, including the diagnosis of molec-
ular relapse, were circulated. Out of 1045 patients, we
received completed DLI questionnaires from 344 patients
from 31 centers; therefore, 701 failed to complete a ques-
tionnaire. Out of the 344 patients who did provide a com-
pleted questionnaire, 156 (45%) were excluded from the
analysis as their relapse had first been detected at a more
advanced stage than molecular relapse. Patients in whom
the type of relapse was not known (n=33) were also not
included in the study. The study, therefore, included 155
patients who had been diagnosed with molecular relapse.
Definitions
Donor lymphocyte infusion
Lymphocytes were collected from the donors by leukapheresis
on one or more occasions. Infusions had to be given on multiple
days at least seven days apart to be counted as separate infusions.
Thirty-four (10%) patients treated with DLI had active GvHD at
the time of infusion and 27 patients (8%) were still receiving some
form of immunosuppressive therapy. Ten patients received con-
comitant imatinib therapy with DLI.
Relapse
Relapse was classified as molecular (i.e. any level of BCR-ABL
transcripts detected by quantitative reverse transcription–poly-
merase chain reaction (RT-PCR) in 2 consecutive tests performed
over a minimum of 4 weeks), cytogenetic (i.e. reappearance of one
or more Philadelphia chromosome–positive (Ph+) metaphases at
bone marrow cytogenetics), or hematologic (i.e. presence of
peripheral blood leukocytosis accompanied by a hypercellular
bone marrow with Ph+ chromosome on cytogenetic analysis) in
accordance with previous reports.11,13,14 CML phase was classified
in accordance with criteria proposed by Speck et al.15
Statistical analysis
Overall survival was calculated from the date of the first infu-
sion of donor lymphocytes until death or last follow up. Event-free
survival (EFS) was calculated from the date of the first infusion of
donor cells until event or last follow-up. An event was defined as
DLI for CML molecular relapse after allo-BMT for CML
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Table 1. Outcome of patients receiving DLI for CML molecular relapse.
N.                                                                                    155
Acute GvHD post-DLI
Grade 0                                                                                     88 (57%)
Grade I                                                                                     19 (12%)
Grade II-                                                                                    11 (7%)
Grade III-IV                                                                              12 (8%)
Unknown                                                                                  25 (16%)
Chronic GvHD post-DLI
No                                                                                                89 (57%)
Yes                                                                                               34 (22%)
Unknown                                                                                    32 (21%)
Best response to DLI
Molecular CR                                                                            95 (61%)
Cytogenetic CR                                                                           8 (5%)
Hematologic CR or CP                                                              3 (2%)
No response                                                                             28 (18%)
Unknown                                                                                    21 (14%)
Interval from first DLI to best response (days)            245 (9-1673)
DLI-related mortality                                                       11 (95% CI 6-18%)
Overall survival                                                              78 % (95% CI 72-80%)
Response to DLI from alive patients
Yes                                                                                               93 (75%)
No                                                                                               16 (13%)
Unknown                                                                                   15 (12%)
Complete molecular response of responders                  86 (69%)
5 years OS                                                                         P
All patients 76% (95% CI: 72-80%)
Identical siblings 89% (95% CI: 81-97%)                0.003
Unrelated donors 63% (95% CI: 50-76%)     
< 6 months after 69% (95% CI: 55-85%)
molecular relapse                                    0.061
> 6 months after 81%  (95% CI: 71-91%)                    
molecular relapse
DLI given for molecular 81% (95% CI: 70-92%)
relapse
DLI given for cytogenetic, 71% (95% CI: 59-83%)                 0.26
hematologic or advanced 
phase relapse
DLI: donor lymphocyte infusion; GvHD: graft-versus-host disease; CR: complete response;
CP: chronic phase; OS: overall survival.
Table 2. Response to DLI by disease stage at the time DLI was given.
N.                                                                                      155
DLI given in molecular relapse                                                  N=85
Molecular CR                                                                            50 (59%)
Cytogenetic CR                                                                          5 (6%)
No or Unknown Response                                           14 + 16= 30 (35%)
DLI given in cytogenetic relapse                                                N=37
Molecular CR                                                                            27 (73%)
Cytogenetic CR                                                                          2  (5%)
Hematologic CR                                                                       1  (2.5%)
No or Unknown Response                                                5+2=7  (19%)
DLI given in hematologic CP                                                       N=25
Molecular CR                                                                             16 (64%)
Cytogenetic CR                                                                                 0
Hematologic CR                                                                         1  (4%)
No or Unknown Response                                                 6+ 2=8 (32%)
DLI given in advance phase relapse (AP/BC)                          N=8
Molecular CR                                                                               2 (25%)
Cytogenetic CR                                                                          1 (12.5%)
Hematologic CR or CP                                                              1(12.5%)
No                                                                                                   4 (50%)
DLI: donor lymphocyte infusion; CR: complete response; CP: chronic phase; AP: acceler-
ated phase; BC: blast crisis. 
relapse after response or, in patients not responding, as progres-
sion to more advanced disease (e.g. from cytogenetic relapse to
hematologic relapse or from chronic phase to accelerated phase),
or death if neither relapse nor progression occurred. 
Survival curves for OS and EFS were calculated using the
Kaplan-Meier method.16 The cumulative incidence of DLI-related
mortality was calculated from the date of the first infusion of
donor lymphocytes considering death without prior relapse or dis-
ease progression to frank hematologic relapse as failure of the
event of interest and relapse or progression as competing event;
patients alive relapse-free were censored at last follow up. The
cumulative incidence method was used also for estimates of
GvHD and response, considering death without the event of inter-
est as competing risk.
Results
This study included 155 patients transplanted between
1986 and 2003 in 28 EBMT centers. None were treated
with imatinib prior to transplant. As stated above, all
patients presented first with molecular relapse and subse-
quently received DLI either at the same stage, i.e. in
molecular relapse (n=85), or upon progression to cytoge-
netic (n=37), hematologic in chronic phase (n=25) or more
advanced phase (n=8) disease (Online Supplementary Table
S1).  However, 19 patients received another therapy prior
to DLI: 16 patients in advanced stage and 3 in molecular
relapse (9 had interferon-alpha, 6 hydroxyurea, one
hydroxyurea and etoposide, one cytarabine, one imatinib,
one mitoxantrone). At the time of analysis, the median
follow up after DLI of surviving patients was 46 months
(range 3-135 months). Patients’ characteristics, type of
transplant received, disease stage at time of DLI, acute and
chronic GvHD post-transplantation, details of DLI, timing
of DLI with respect to the date of transplant, number of
DLI, T-cell dose received, interval from relapse to DLI
received and reason for giving DLI (i.e. planned, for molec-
Y. Chalandon et al.
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Figure 1. OS and CI of DLI-related mortality. (A) 5 years OS from first
DLI of all patients of 76% (95%CI: 72-80%). (B) 5-year CI of DLI-relat-
ed mortality from first DLI for all patients 11% (95%CI: 6-18%).
Table 3. Multivariate analysis for overall survival.
Parameters HR Lower Higher P
95% CI: 95% CI: value
Time from molecular 0.4 0.19 0.84 0.018
relapse to DLI 
>6 months better
Type of donor
Unrelated donor worse 2.54 1.15 5.63 0.021
Type of relapse 1.50 0.69 3.25 0.30
A
B
A
B
76% (72-80%)
11% (6-18%)
Years
Years
Years
P=0.004
P=0.003
UD, n=71, 63% (50-76%)
UD, n=71, 19% (11-32%)
ID-SIB, n=84, 89% (81-97%)
ID-SIB, n=84, 3% (1-11%)
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Figure 2. OS and CI of DLI-related mortality. (A) 5-year OS from first
DLI from identical sibling of 89 % (95%CI: 81-97 %) vs. 63% (95%CI:
50-76%) from unrelated donors; P=0.003  (B) 5-year CI of DLI-related
mortality from first DLI for identical sibling donors of 3% (95%CI: 1-
11%) vs. 19% (95%CI: 11-32%) for unrelated donors; P=0.004.
ular relapse, for progressive disease) are detailed in the
Online Supplementary Table S1. 
The median time from HSCT to molecular relapse was
239 days (range 30-4274 days), from HSCT to first DLI was
580 days (range 69-4296 days), and from molecular relapse
to first DLI was 210 days (range 0-1673 days). A total of 64
(41%) patients received DLI within six months of the detec-
tion of the molecular relapse. No information regarding the
reasons for receiving DLI early (within 6 months) or late
(after 6 months) was available. The median time to DLI
administration from transplant for patients treated in molec-
ular relapse, in cytogenetic relapse, in hematologic relapse or
in advanced phase were 133 days (range 0-1154 days), 211
days (range 0-1673 days), 335 days (range 134-1526 days),
and 405 days (range 180-1019 days), respectively.
Details regarding the outcome of patients who received
DLI after molecular relapse are specified in Table 1. The
median interval to either molecular, cytogenetic or hema-
tologic response after DLI was 245 days (range 9-1673
days). The median initial cell dose in patients who
received DLI for molecular relapse was 5x106 CD3+
cells/kg (range 0.01-100) and 40% received only one DLI
dose (median 2, range 1-14).  On the other hand, for the
patients who received DLI for disease beyond molecular
relapse, the median initial cell dose was higher at 10x106
CD3+ cells/kg (range 0.5-712.5) and more patients (52%)
received only one DLI dose (median 1, range 1-5).  Eighty-
five percent of the survivors and 68% of all patients
included in the study responded to DLI, with the majority
of them obtaining complete molecular remission (77% of
survivors and 61% of all the patients). Table 2 shows the
response rate of patients who received DLI while still in
DLI for CML molecular relapse after allo-BMT for CML
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Figure 3. OS and CI of DLI-related mortality. (A) 5-year OS from first
DLI for patient receiving DLI before six months after molecular
relapse of 69% (95%CI: 55-83%) vs. 81% (95%CI: 71-91%) for
patients receiving it after six months; P=0.061. (B) 5 years CI of DLI-
related mortality from first DLI for patient receiving DLI before six
months after molecular relapse of 16% (95%CI: 8-31%) vs. 6%
(95%CI: 2-16%) for patients receiving it after six months; P=0.03.
Figure 4. OS and CI of DLI-related mortality. (A) 5-year OS from first
DLI for molecular relapses of 81 % (95%CI: 70-92%) vs. 71% (95%CI:
59-83%) for other type of relapses; P=0.26. (B) 5-year CI of DLI-relat-
ed mortality from first DLI for molecular relapses of 11 % (95%CI: 5-
23%) vs. 10% (95%CI: 5-21%) for other type of relapses; P=0.9.
Table 4. Multivariate analysis for DLI-related mortality.
Parameters HR Lower Higher P
95% CI: 95% CI: value
Time from molecular 0.31 0.09 1.11 0.071
relapse to DLI 
>6 months better
Type of donor 5.78 1.26 26.64 0.024
Unrelated donor worse
Disease stage at  DLI 0.97 0.29 3.28 0.96
A
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A
B
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Years
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Years
P=0.03
P=0.9
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n=88, 6% (2-16%)
DLI > 6m
molecular relapse and those receiving DLI after progress-
ing to more advanced phases.
The cumulative incidence of GvHD (acute and chronic)
after DLI at five years was 38% (95%CI: 30-48%) which
was lower for identical sibling transplants at 27% (95%CI:
18-41%) compared to unrelated donor transplants at 50%
(95%CI: 38-66%), (P=0.014), with a trend towards  a high-
er incidence at 45% (95%CI: 32-62%) if given within six
months of molecular relapse compared to 34% (95%CI:
25-47%) when given beyond six months (P=0.1).
The 5-year cumulative incidence of molecular, cytoge-
netic or hematologic response to DLI was 83% (95%CI:
77-91%), with no differences between the type of donors,
82% (95%CI: 73-91%) and 79% (95%CI: 69-90%) for
identical sibling and unrelated donors, respectively, or the
time when the DLI was given, 81% (95%CI: 70-92%) and
82% (95%CI: 73-92%) for before or after six months from
the time of molecular relapse, respectively.
The 5-year overall survival (OS) post-DLI was 76%
(95%CI: 72-80%) for all patients (Table 1 and Figure 1A).
The 5-year OS was 89% (95%CI: 81-97%) for identical
sibling and 63% (95%CI: 50-76%) for unrelated donors
(P=0.003) (Table 1 and Figure 2A). There was a trend to
better OS when comparing patients who received DLI
after six months versus those who received it before six
months from molecular relapse, 81% (95%CI: 71-91%)
and 69% (95%CI: 55-85%) respectively (P=0.061) (Table 1
and Figure 3A). There was no statistically significant dif-
ference if DLI was given for molecular relapse (81%;
95%CI: 70-92%) or for other type of relapses (71%;
95%CI: 59-83%) (P=0.26) (Table 1 and Figure 4).
Death from DLI-related mortality was 11% at five years
(95%CI: 6-18%) (Figure 1B) with 80% of the patients alive
at last follow up. DLI-related mortality was associated
with the type of donor with a 5-year CI of DLI-related
mortality significantly worse for patients with unrelated
donors (19%; 95%CI: 11-32%) compared to identical sib-
ling donors (3%; 95%CI: 1-11%) (P=0.004) (Figure 2B). It
was also associated with the timing of DLI, worse when
DLI was given within six months of molecular relapse
(16%; 95%CI: 8-31%) compared to DLI given later (6%;
95%CI: 2-16%) (P=0.03) (Figure 3B). Disease stage at DLI
did not have any impact on DLI-related mortality: 11%
(95%CI: 5-23%) for patients receiving DLI for molecular
relapse and 10% (95%CI: 5-21%) for those receiving DLI
for more advanced relapses (P=0.9) (Figure 4B).
Thirty-one patients out of 155 died: 15 from relapse, 14
from DLI-related complications (7 from infections, 5 from
GvHD and 2 were unknown), and 2 from non-DLI- or
CML-related causes.
In a multivariate analysis of OS, the two factors that had
an impact were the type of donor (unrelated donors hav-
ing a worse outcome, i.e. HR 2.54; 95%CI: 1.15-5.53;
P=0.021)  and the time from molecular relapse to first DLI,
DLI given after six months being better (HR 0.4; 95%CI:
0.19-0.84; P=0.018) (Table 3).  Starting dose, prior T-cell
depletion, disease stage at DLI, donor recipient sex combi-
nation, age and prior acute or chronic GvHD were not sig-
nificant and in multivariate analysis of DLI-related mortal-
ity the only factor that remained statistically significant
was the type of donor, unrelated donors having again a
worse outcome (HR 5.78; 95%CI: 1.26-26.64; P=0.024)
(Table 4). There was a tendency for a better outcome
regarding the time from molecular relapse to first DLI for
patients receiving DLI after six months post molecular
relapse (HR 0.31; 95%CI: 0.09-1.1; P=0.071) (Table 4).
Disease stage at DLI was not associated with outcome. 
The event free survival post-DLI for the entire group
was 63% (95% CI: 57-69%).
Discussion
This study describes the outcome of patients who
received DLI after detection of isolated molecular relapse
after allogeneic HSCT for CML in a period in which TKI
were not widely available and, therefore, DLI was the
most commonly used strategy to treat CML patients
relapsing after transplantation. It compares the outcome of
patients who received DLI for different types of relapses
through data extracted from the EBMT registry. 
This study has several limitations. It is retrospective,
multicentric and spans a period of 20 years (1983-2003).
However, very few patients (6%) had received TKI and,
therefore, the interpretation of the data is not confounded
by TKI therapy. The 155 patients studied are a sample of
1045 patients in the EBMT database treated by DLI for
relapse. Again, this cohort was selected for having been
diagnosed with molecular relapse after HSCT and having
received DLI between 1993 and 2004. A comparison of
base-line characteristics and outcome of patients included
in this cohort with patients in the database not considered
for this study does not show any major differences (data
not shown). Patients received DLI at different time points,
i.e. upon diagnosis of molecular relapse or later. The rea-
sons behind the timing of DLI are not known. This cohort
is subject to some potential biases, as we cannot exclude
that some patients programmed to receive DLI late did not
receive it because of rapid disease progression. Our major
finding of less DLI-related mortality in recipients of late as
compared to early DLI should not be greatly influenced by
this fact. The most appropriate analysis for this type of
data is a multistate model capturing all patients at the time
of molecular relapse and comparing outcome with differ-
ent types of intervention. It is obvious that this type of
analysis cannot be conducted with the current dataset.
This study confirms previous analyses that showed that
DLI is highly efficient in rescuing CML relapsing patients
post allogeneic HSCT,13,14,17,18 that unrelated donors had a
worse OS, as did patients receiving DLI prior to six
months after relapse,14,17 and that this poorer outcome was
mainly associated to a higher DLI-related mortality.
Unrelated donor transplant patients had a 2.5-fold high-
er risk of death after DLI when compared to sibling donors
and patients receiving DLI more than six months after
relapse a 2.5-fold lower risk of death when compared to
patients receiving DLI within six months. DLI-related
mortality was 5.5-fold higher for unrelated donors and 3-
fold lower for patients receiving late DLI.
However, what was interesting and also quite surprising
was that giving DLI early after first detection of molecular
relapse had similar outcomes in terms of response to DLI,
OS or DLI-related mortality as compared to DLI given in
more advanced relapse types such as cytogenetic or hema-
tologic relapses. In fact, there was an inverse correlation
between timing of DLI and disease stage at DLI as more
patients receiving DLI within six months of relapse
received them for molecular relapse compared with more
patients receiving DLI after six months of relapse who did
so at a more advanced disease stage. There also was no
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correlation between the time intervals from transplant to
relapse and from relapse to DLI suggesting that it was not
patients experiencing early relapse who received DLI ear-
lier (data not shown). Obviously, we cannot exclude the
possibility that patients with a more aggressive relapse
(i.e. high and rapidly increasing transcript levels) were pre-
dominantly given DLI within six months of the relapse
being diagnosed. Conversely, it is also possible that
patients who received DLI after six months from diagnosis
of relapse had low and stable levels of BCR-ABL tran-
scripts. In addition, the availability of the donor to donate
lymphocytes, the spread of the knowledge of the efficacy
of DLI over the years, and other reasons may have impact-
ed on the decision to give DLI before or after six months
of the detection of the molecular relapse. 
Nevertheless, in our hands, donor type and timing of
DLI had a strong impact on long-term survival but disease
stage at relapse had a smaller impact, and not through
DLI-related mortality but through CML-related mortality.
To the best of our knowledge, this is the first study that
has analyzed this factor in detail. This message is rather
counterintuitive as one would normally think that the
sooner the treatment for relapse is delivered, the better.
This finding may be related to the particular natural course
and biology of the disease, as CML is usually a slowly
evolving disease and patients in cytogenetic or hematolog-
ic relapses will still have some months or years before
advancing to blast phase and death. Another contributing
factor might be a certain degree of residual GvL effect that
would differentiate this situation from a molecular relapse
occurring after first-line TKI therapy.  
We should very cautiously limit our interpretation to
patients who after relapse remain in molecular, cytogenet-
ic or hematologic chronic phase and should not translate
our findings into the more advanced phases since there
were too few patients in accelerated or blastic phases in
our cohort and we could not, therefore, specifically exam-
ine these categories. Nevertheless, previous studies have
shown that DLI given to patients in CML chronic phase
resulted in a better outcome with a survival of approxi-
mately 76-79% compared to 12-28% in advanced phas-
es.5,7
Another interesting question that follows on from this is
that the best moment to give DLI after molecular detec-
tion of relapse might not be immediately after it occurs.
Our results suggest that it might be possible to follow the
patient closely and decide to treat him at a later time
point, even after progression to cytogenetic or hematolog-
ic chronic phase relapse. This strategy might impact favor-
ably on the DLI-associated mortality as, according to our
findings, having DLI later than six months after the detec-
tion of molecular relapse might be safer. It seems that,
although there is no clear time point that we could recom-
mend, DLI could be postponed despite molecular evidence
of relapse and be given no later than in hematologic chron-
ic phase relapse, in line with previous reports that showed
that DLI given at least two years after allogeneic HSCT
had a lower risk of leading to GvHD.14,19
This issue now becomes even more complicated in the
era of TKI. Patients could receive TKI for posttransplant
relapse20,21 or DLI or both.1 If one plans to give both thera-
pies, should they be given sequentially (and in which
order) or concomitantly? In addition, whether the use of a
TKI at the very early signs of molecular relapse or simply
observing untreated molecular relapse could jeopardize
the efficacy of subsequent DLI is also an important ques-
tion.
Nevertheless, these data should constitute the bench-
mark for a future comparative study of patients treated
with TKI at the time of molecular relapse.
Appendix: EBMT centers [center number]
J Apperley, Hammersmith Hospital, London, UK [205], G.
Socié, Hôpital Saint-Louis, Paris, France [207], U. Schanz,
University Hospital of Zürich, Switzerland [208], M. Boogaerts,
University Hospital of Leuven, Leuven, Belgium [209], P.
Ljungman, Huddinge University Hospital, Huddinge, Sweden
[212], M. Rovira, Hospital Clinic Institute of Hematology and
Oncology, Barcelona, Spain [214], D. Bron, Institut Jules Bordet,
Brussels, Belgium [215], A. Broom, Western General Hospital,
Edinburgh, Scotland, UK [228], R. Foa, Univ. La Sapienza,
Rome, Italy [232], X. Poiré, Cliniques Universitaires St. Luc,
Brussels, Belgium [234], A. Schattenberg, Univ.Med.Cent.St.
Radboud, Nijmegen, The Netherlands [237], B. Bandini,
Hospital San Orsola, Bologna, Italy [240], P. Veys, Great
Ormond Street Hospital for Children, London, UK [243], P.
Chevallier, CHU, Nantes, France [253], Y.Chalandon, Hôpital
Cantonal Universitaire, Geneva, Switzerland [261], V. Leblond,
Pitie-Salpetriere, Paris, France [262], I. Yakoub-Agha, Hopital
Claude Huriez, Lille, France [277], S. Paneesha, Birmingham
Heartlands Hospital, Birmingham, UK [284], G. Irrera,
Azienda Ospedaliera Centro Unico Regionale Trapianti Alberto
Neri, Bianchi-Melacrino-Morel, Italy [587], N. Kröger,
University Hospital Eppendorf , Hamburg, Germany [614], A
Vitek, Institute of Hematology and Blood transfusion, Prague,
Czech Republic [656], N.H. Russel, Nottingam City Hospital,
Nottingam, UK [717], P. Jindra, Charles University Hospital,
Pilsen, Czech Republic [718], J. San Miguel, Hospital Clinico,
Salamanca, Spain [727], G. de Rosa, Univeristy of Napoli,
Napoli, Italy [766], A. Bloor, Christie NHS Trust Hospital,
Manchester, United Kingdom [780] A Butler, Canterbury Health
Laboratories, Christchurch, New Zeland [798], R. Arnold,
Charité Universitätsmedicine, Berlin, Germany [807], J. Finke,
University Hospital Freiburg, Freiburg, Germany [810], H.
Ludwig, Wilhelminespital, Vienna, Austria [828].
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